Adding of sitagliptin phosphate hydrate to combination therapy with pegylated interferon alpha 2b and ribavirin for patients with chronic hepatitis C and diabetes mellitus

Adding of sitagliptin phosphate hydrate to combination therapy with pegylated interferon alpha 2b and ribavirin for patients with chronic hepatitis C and diabetes mellitus - ASPIRIN trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003775

Enrollment

Registered

2010-06-21

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic hepatitis C and hyperglycemia

Interventions

sitagliptin phosphate hydrate pegylated interferon alpha 2b ribavirin pegylated interferon alpha 2b ribavirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C HCV serotype 1 HCV viral load; over 5 log copies/mL Fasting blood sugar: over 105 mg/dL

Exclusion criteria

Exclusion criteria: pregnant woman drug allergy insulin medication depression autoimmune diseases malignant diseases

Design outcomes

Primary

Measure	Time frame
Sustained viral response of HCV	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026